A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS,AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND CC-99282 IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
Protocol #22-0939
Location: CTRC Inpatient, University of Colorado Hospital
|
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
Protocol #22-0565
Location: University of Colorado Hospital
|
ANHL1931- A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Protocol #21-4667
Location: Childrens Hospital Colorado
|
Do decreased dietary fat and increased fiber reduce recurrence of Clostridioides difficile infection in oncology patients?
Protocol #21-2851
Location: Childrens Hospital Colorado, University of Colorado Hospital
|
LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS
Protocol #19-0561
Location: University of Colorado Hospital
|
PHASE 1/2 DOSE ESCALATION AND PRELIMINARY EFFICACY OF CD19 DIRECTED CAR T CELLS GENERATED USING THE MILTENYI CLINIMACS PRODIGY SYSTEM (UCD19 CART) IN PEDIATRIC PATIENTS WITH REPLASED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) AND B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL)
Protocol #18-2424
Location: Childrens Hospital Colorado
|
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies
Protocol #22-1252
Location: CTRC Inpatient, University of Colorado Hospital
|
Symptom Screening Linked to Care Pathways for Children with Cancer: a Cluster Randomized Trial
Protocol #20-2525
Location: Childrens Hospital Colorado
|
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Protocol #20-0680
Location: Childrens Hospital Colorado
|
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Protocol #19-2631
Location: Childrens Hospital Colorado
|
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)
Protocol #19-2438
Location: Childrens Hospital Colorado
|
Total Joint Arthroplasty in a Pediatric Population
Involves two surveys for approximately 10 mintues...
Protocol #19-0306
Location: Childrens Hospital Colorado
|
APEC1621-MASTER, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Protocol #17-2168
Location: Childrens Hospital Colorado
|
051/02 A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Protocol #16-0064
Location: Childrens Hospital Colorado
|
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Protocol #22-2360
Location: Childrens Hospital Colorado
|
An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
Protocol #21-4778
Location: CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sezary Syndrome
Protocol #19-2524
Location: University of Colorado Hospital
|
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
Protocol #20-2584
Location: University of Colorado Hospital
|
COG AALL1731 - A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Protocol #19-1634
Location: Childrens Hospital Colorado
|
PEPN2011: A Phase 1/2 Study of Tegavivint (IND#156033, NSC#826393) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
For Patients on Part A: D with a solid tumor, lymphoma or desmoid tumor that has either come back or does not respond to therapy, or a desmoid tumor that cannot be removed safely by surgery.
For Patients on Part B: Diagnosed with a relapsed or refractory Ewing sarcoma, desmoid tumor, os...
Protocol #21-4712
Location: Childrens Hospital Colorado
|
